Document is current
Any future updates will be listed below
-
Authors
Berressem, Scarlett
Moos, Lars-Thorben
Röder, Johanna
Harzheim, Laura
Dreiack, Nils
Brodersen, Marlene
Kron, Florian
Dengler, Robert
Reinhardt, Hans Christian
Utzig, Martin
Illmer, Thomas
Wolf, Jürgen
Kron, Anna
-
Funding
Funding for this research was provided by:
Universitätsklinikum Köln
- License Information
-
More Information
Article History
Received: 6 July 2025
Accepted: 1 December 2025
First Online: 12 December 2025
Declarations
:
: Consultation with the ethics committees of the University of Cologne and the University of Duisburg-Essen has taken place. Accordingly, an ethics vote was deemed unnecessary. Likewise, no informed consent was required.
: Not applicable.
: H.C.R. received consulting and lecture fees from Novartis, Roche, Janssen, Lilly, Takeda, Abbvie, AstraZeneca, Vertex and Merck. H.C.R. received research funding from AstraZeneca and Gilead Pharmaceuticals. H.C.R. is a co-founder of CDL Therapeutics GmbH. The remaining authors declare no competing financial interest.
: The remaining authors declare no competing financial interest.
